SandboxAQ Launches Virtual Drug Screening Software
SandboxAQ has released AQPotency, a software tool for ultrafast virtual screening in drug discovery, eliminating the need for solved protein structures. The service is now available via Claude.
SandboxAQ has announced the general availability of AQPotency, a large quantitative model designed to predict the efficacy of potential drug compounds. This new software aims to accelerate the drug discovery process by enabling virtual screening without requiring a pre-determined protein structure.
The AQPotency tool utilizes advanced quantitative modeling to assess how effectively a potential drug will bind to and interact with its target molecule. This virtual approach significantly speeds up early-stage research compared to traditional experimental methods that often depend on detailed knowledge of protein structures.
Announced on August 19, 2026, the software is now accessible through the Claude platform via the Model Context Protocol (MCP). This integration expands the accessibility of the tool for researchers in the pharmaceutical and biotechnology sectors.
By enabling rapid virtual assessment of drug candidates, AQPotency is expected to help researchers identify promising compounds more quickly. This could potentially shorten the timeline for bringing new medicines to market and reduce overall development costs.